BARCELONA, Spain and CAMBRIDGE, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that Dr. Tamara Maes, Oryzon’s Chief Scientific Officer, is scheduled to present at the Epigenetics in Drug Discovery Workshop being held on January 26-27, 2016 in Cambridge, UK.
Dr. Maes is scheduled to present on Wednesday, January 27th 2016 at 11:15 AM GMT. The presentation titled, “ORY-2001 - An Epigenetic Approach to Treat Alzheimer's Disease and other Neurodegenerative Disorders”, will take place at The Buckingham House.
Dr. Maes commented, “Epigenetics is a new frontier in discovering treatment of various diseases. We will present encouraging data from our preclinical studies for ORY-2001, a dual LSD1/MAO-B inhibitor. The data show the compound improves memory in Alzheimer Disease and Huntington Disease mice models. We believe our program has shown promising data for the treatment for various neurodegenerative disorders.”
The Epigenetics in Drug Discovery Workshop gathers researchers, academicians and industry professionals who contribute to epigenetics research. The workshop is dedicated to exploring the potential of epigenetics towards novel and existing therapeutics, across significant areas of unmet need. The workshop consists of presentations on emerging technologies, epigenetic changes and cellular reprogramming with special interest in drug discovery and development.
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015), is a clinical stage biopharmaceutical company considered the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. Oryzon’s LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one is anticipated to enter clinical trials in early 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.
This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions.
Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public.
Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A, have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
US Contact: The Ruth Group Lee Roth/Tram Bui (646) 536-7012/7035 firstname.lastname@example.org email@example.com Spain: ATREVIA Ana Melgar/Patricia Cobo IR Director +34 91 564 07 25 firstname.lastname@example.org email@example.com The Company: Ms. Anna K Baran +44 (0) 752 1083 006 firstname.lastname@example.org